Christopher G. White - 03 Feb 2022 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Business Officer
Signature
/s/ Donald Notman, Attorney-in-Fact for Christopher G. White
Issuer symbol
OCUL
Transactions as of
03 Feb 2022
Net transactions value
$0
Form type
4
Filing time
07 Feb 2022, 18:31:04 UTC
Previous filing
08 Oct 2021
Next filing
14 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +50,000 +2351% $0.000000 52,127 03 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 03 Feb 2022 Common Stock 150,000 $5.27 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 Includes (i) 50,000 shares of common stock of the Company underlying unvested RSUs and (ii) 2,127 shares of the Company's common stock acquired under the 2014 Ocular Therapuetix, Inc. Employee Stock Purchase Plan on December 31, 2021.
F3 Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.